Risk Factors for Subclinical Diabetic Peripheral Neuropathy in Type 2 Diabetes Mellitus
Li Gao,Jiexing Qin,Ying Chen,Wenqun Jiang,Desheng Zhu,Xiajun Zhou,Jie Ding,Huiying Qiu,Yan Zhou,Qing Dong,Yangtai Guan
DOI: https://doi.org/10.2147/dmso.s433024
2024-01-26
Diabetes Metabolic Syndrome and Obesity Targets and Therapy
Abstract:Li Gao, 1, &ast Jiexing Qin, 1, &ast Ying Chen, 1 Wenqun Jiang, 2 Desheng Zhu, 1 Xiajun Zhou, 1 Jie Ding, 1 Huiying Qiu, 1 Yan Zhou, 1 Qing Dong, 1 Yangtai Guan 1 1 Department of Neurology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China; 2 Department of Laboratory Medicine, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Qing Dong; Yangtai Guan, Department of Neurology, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200127, People's Republic of China, Email ; Purpose: To investigate the risk factors associated with subclinical diabetic peripheral neuropathy (sDPN) in patients with type 2 diabetes mellitus (T2DM). Patients and Methods: This cross-sectional, retrospective study involved 311 patients with T2DM who were successively admitted from January 2018 to December 2021 without any neurological symptoms. All participants underwent a nerve conduction study (NCS), and those asymptomatic patients with abnormal nerve conduction were diagnosed with sDPN. Differences between groups were evaluated by the chi-squared, Wilcoxon, or Fisher's exact test. Binary logistic regression analysis was performed to determine the independent risk factors for sDPN. Receiver operating characteristic (ROC) curves were constructed, and the areas under curves (AUCs) were detected. Results: Among 311 asymptomatic patients with T2DM, 142 (45.7%) with abnormal nerve conduction were diagnosed with sDPN. Patients with sDPN significantly differed from those without diabetic peripheral neuropathy (DPN) in age, history of hypertension, duration of diabetes, anemia, neutrophil-to-lymphocyte ratio, fasting C-peptide level, serum creatinine level, and albuminuria (all p < 0.05). Furthermore, the duration of diabetes (odds ratio [OR]: 1.062, 95% confidence interval [CI]: 1.016– 1.110), fasting C-peptide level (OR: 2.427, 95% CI: 1.126– 5.231), and presence of albuminuria (OR: 2.481, 95% CI: 1.406– 4.380) were independently associated with the development of sDPN (all p < 0.05). The AUCs for fasting C-peptide level, duration of diabetes, and the two factors combined were 0.6229 (95% CI: 0.5603– 0.6855, p =0.0002), 0.6738 (95% CI: 0.6142– 0.7333, p < 0.0001), and 0.6808 (95% CI: 0.6212– 0.7404, p < 0.0001), respectively. Conclusion: For patients with T2DM and longer duration of diabetes, lower fasting C-peptide levels, and presence with albuminuria, the risk for developing DPN is higher even if they have no clinical signs or symptoms. Identifying potential risk factors for the development of sDPN and effectively controlling them early are critical for the successful management of DPN. Keywords: type 2 diabetes mellitus, subclinical diabetic peripheral neuropathy, nerve conduction study, fasting C-peptide, albuminuria, risk factor Diabetic peripheral neuropathy (DPN) is one of the most prevalent and disabling complications of diabetes mellitus (DM), which occurs in more than half of affected individuals. 1 Chronic hyperglycemia and various pathophysiological changes have been reported to cause damage to the nervous system. 2 The most common symptoms of DPN are limb pain and numbness, which eventually lead to foot ulcer, gangrene, and amputation, causing great pain to patients and leading to long-term disability. However, early manifestations of DPN are often overlooked until it is well established, at which point it is often irreversible. Subclinical DPN (sDPN) refers to the existence of neurological abnormalities in a nerve conduction study (NCS) or measurement of small fiber neuropathies, but without any neurological symptoms or signs. 3 Some previous studies reported that more than 25% patients with T2DM may develop DPN, although up to half of them may remain asymptomatic. 4,5 Clinically, the diagnosis of DPN often depends on the presence of patient-reported symptoms and physical signs, thus delaying the detection of sDPN. However, the use of NCS can increase the diagnostic yield of sDPN, from one-third at baseline to nearly two-thirds during the follow-up of 5 years. 6 Therefore, identifying sDPN at an early stage and detecting the predisposing factors for its development may slow, stop, or even reverse the progression of DPN and avoid the occurrence of DPN-related morbidity and complications. Some recent studies have addressed that multiple risk factors such as age, disease durati -Abstract Truncated-
endocrinology & metabolism